Last year saw heightened market volatility, marked by international trade disputes, regulatory unrest, and a general feeling of uncertainty – but 2019 is off to a strong start with several multi-billion dollar deals.
The industry today celebrates Clinical Trials Day 2019, with events that will help promote awareness and a better understanding of study participation barriers, says ACRP, which aims to pilot a new initiative to advance the workforce early next year.
Increasingly concerned with the potential for cyber attacks at third-party vendors, pharma looks to gain visibility into supplier performance, says industry expert after the recent breach at Charles River.
Synteract adds to its therapeutic centers of development, Sterling Pharma continues growth in the US, and WCG’s site division sees the addition of several executives, among other people on the move this month.
Hu-manity.co acquires Betterpath in a deal that will see both patients and pharma gain access to some 80% of health care’s “dark data” – information that comes with explicit consent under fair trade practices, which is not only a good ethical posture,...
Clinical trials are less safe today as researchers are inundated with increasing amounts of data and new processes developed in part by CROs, which have created “tier upon tier of bureaucracy,” argues industry expert, who warns that things are getting...
An international coalition of health integrity groups today demands that European universities must make clinical trial results public – with 83% all of due trials still unreported, according to a new report.
The Australian Government commits $100m to support rural, regional, and remote clinical trials – recognizing the importance of a “vibrant clinical trial ecosystem in underpinning a world-class health care system,” says industry expert.
Centralized databases, reduced competition for patients, and higher starting doses are among some of the benefits to conducting research in Poland, which ranks seventh in Europe for clinical trial participation, says Moleculin CEO.
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.